TR200100377T2 - Aß Protein üretimi inhibitörleri olarak sukinoilamino laktamlar. - Google Patents

Aß Protein üretimi inhibitörleri olarak sukinoilamino laktamlar.

Info

Publication number
TR200100377T2
TR200100377T2 TR2001/00377T TR200100377T TR200100377T2 TR 200100377 T2 TR200100377 T2 TR 200100377T2 TR 2001/00377 T TR2001/00377 T TR 2001/00377T TR 200100377 T TR200100377 T TR 200100377T TR 200100377 T2 TR200100377 T2 TR 200100377T2
Authority
TR
Turkey
Prior art keywords
lactams
prevent
sucinoylamino
amyloid
protein production
Prior art date
Application number
TR2001/00377T
Other languages
English (en)
Inventor
E. Olson Richard
P. Maduskuie Thomas
Andrew Thomas Lorin
Original Assignee
Dupont Pharmaceuticals Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dupont Pharmaceuticals Company filed Critical Dupont Pharmaceuticals Company
Publication of TR200100377T2 publication Critical patent/TR200100377T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Bu bulus, ilaç ve biyo-etkileyici özellikler tasiyan Formül (I)'e ait yeni laktamlar veya farmasötik açidan kabul gören tuzlar veya bunlarin ön ilaci, bunlarin farmasötik kompozisyonlari ve kullanim metotlari ile ilgilidir. Bu yeni bilesikler, amiloid öncü proteininin islemesini önler ve daha özel olarak da Abeta-peptit üretimini önler ve böylece amiloid proteininin nörolojik tortularinin olusmasini engelleyecek sekilde hareket eder. Daha özel olarak mevcut bulus, Alzheimer hastaligi ve Down sendromu gibi beta-amiloid üretimi ile ilgili nörolojik bozukluklarin tedavisi ile ilgilidir.
TR2001/00377T 1998-08-07 1999-08-07 Aß Protein üretimi inhibitörleri olarak sukinoilamino laktamlar. TR200100377T2 (tr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9569898P 1998-08-07 1998-08-07
US11355898P 1998-12-24 1998-12-24
US12022799P 1999-02-15 1999-02-15
US37008999A 1999-08-06 1999-08-06

Publications (1)

Publication Number Publication Date
TR200100377T2 true TR200100377T2 (tr) 2001-06-21

Family

ID=27377979

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00377T TR200100377T2 (tr) 1998-08-07 1999-08-07 Aß Protein üretimi inhibitörleri olarak sukinoilamino laktamlar.

Country Status (14)

Country Link
US (2) US7304055B2 (tr)
EP (1) EP1102752B1 (tr)
JP (1) JP2003526603A (tr)
CN (1) CN1311779A (tr)
AR (1) AR024197A1 (tr)
AT (1) ATE307117T1 (tr)
AU (1) AU756830B2 (tr)
BR (1) BR9912969A (tr)
CA (1) CA2338944A1 (tr)
DE (1) DE69927827T2 (tr)
ES (1) ES2251838T3 (tr)
HR (1) HRP990246A2 (tr)
TR (1) TR200100377T2 (tr)
WO (1) WO2000007995A1 (tr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038618A2 (en) 1998-12-24 2000-07-06 Du Pont Pharmaceuticals Company SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
CA2377221A1 (en) 1999-09-13 2001-03-22 Bristol-Myers Squibb Pharma Company Hydroxyalkanoyl aminolactams and related structures as inhibitors of a.beta. protein production
AU7997600A (en) 1999-10-08 2001-04-23 Du Pont Pharmaceuticals Company Amino lactam sulfonamides as inhibitors of abeta protein production
AU2001239791A1 (en) 2000-02-17 2001-08-27 Du Pont Pharmaceuticals Company Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
JP2003528150A (ja) * 2000-03-28 2003-09-24 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Ａβタンパク質産生の阻害剤としてのラクタム
US6713476B2 (en) 2000-04-03 2004-03-30 Dupont Pharmaceuticals Company Substituted cycloalkyls as inhibitors of a beta protein production
CA2404273A1 (en) 2000-04-11 2001-10-18 Bristol-Myers Squibb Pharma Company Substituted lactams as inhibitors of a.beta. protein production
AU2001261728A1 (en) * 2000-05-17 2001-11-26 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
CN1251671C (zh) * 2000-05-19 2006-04-19 武田药品工业株式会社 β分泌酶抑制剂
GB0012671D0 (en) 2000-05-24 2000-07-19 Merck Sharp & Dohme Therapeutic agents
NZ516746A (en) * 2000-06-01 2004-02-27 Bristol Myers Squibb Pharma Lactams substituted by cyclic succinates as inhibitors of A-beta protein production
DE10043282A1 (de) * 2000-09-02 2002-03-28 Kurt Heininger Verwendung von Inhibitoren der Amyloid-beta-Protein-Bildung
US7001901B2 (en) 2002-08-27 2006-02-21 Bristol-Myers Squibb Company Tetrazolylpropionamides as inhibitors of Aβ protein production
TW200502221A (en) 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
GB0223038D0 (en) * 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223039D0 (en) * 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
US7342007B2 (en) 2003-03-14 2008-03-11 Astrazeneca Ab Lactams and uses thereof
CN1863797A (zh) 2003-08-08 2006-11-15 先灵公司 具有苯甲酰胺取代基的环胺bace－1抑制剂
TW200524910A (en) 2003-08-08 2005-08-01 Schering Corp Cyclic amine BACE-1 inhibitors having a heterocyclic substituent
WO2005019227A1 (en) * 2003-08-22 2005-03-03 Orchid Chemicals & Pharmaceuticals Ltd Process for the preparation of cephalosporin antibiotic
EP2279741A3 (en) * 2003-12-01 2011-06-01 Cambridge Enterprise Ltd. Caprolactams and their use as anti-inflammatory agents
CN101006051B (zh) * 2004-06-10 2014-09-10 密歇根州州立大学托管理事会 由赖氨酸合成己内酰胺
US7803802B2 (en) 2004-07-22 2010-09-28 Schering Corporation Substituted amide beta secretase inhibitors
AU2006203946B2 (en) * 2005-01-03 2009-07-23 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
JP2010518064A (ja) 2007-02-12 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション Ａｄおよび関連状態の治療のためのピペラジン誘導体
JP5410996B2 (ja) * 2007-02-20 2014-02-05 ボード オブ トラスティーズ オブ ミシガン ステイト ユニバーシティ カプロラクタム製造のための触媒的脱アミノ化
MX2010006972A (es) 2007-12-21 2010-08-26 Ligand Pharm Inc Moduladores selectivos de receptores de andrógenos (sarm) y usos de los mismos.
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
JP2011529087A (ja) * 2008-07-24 2011-12-01 ドラス コーポレイション 環状アミドモノマーを作製する方法、ならびに関連する誘導体および方法
GB201101331D0 (en) * 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
WO2012093733A1 (ja) * 2011-01-07 2012-07-12 セイコーエプソン株式会社 抗シグナルペプチド抗体の製造方法
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
CN104854097A (zh) * 2012-09-21 2015-08-19 百时美施贵宝公司 N-取代的二(氟烷基)-1,4-苯并二氮杂*酮化合物
WO2014047392A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
TWI614238B (zh) * 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
JP2015534554A (ja) 2012-09-21 2015-12-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アルキル，フルオロアルキル−１，４−ベンゾジアゼピノン化合物
WO2014047370A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
JP2015529253A (ja) * 2012-09-21 2015-10-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｎｏｔｃｈ阻害剤としてのフルオロアルキルおよびフルオロシクロアルキル１，４−ベンゾジアゼピノン化合物
EP2897944B1 (en) * 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinone compounds
WO2014047391A1 (en) * 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Prodrugs of 1,4-benzodiazepinone compounds
CN104797584A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 作为notch抑制剂的三环杂环化合物
EP2981267A1 (en) 2013-04-04 2016-02-10 Bristol-Myers Squibb Company Combination therapy for the treatment of proliferative diseases
EP3094323A4 (en) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US552419A (en) * 1895-12-31 Gas generator and burner
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
ZW23187A1 (en) 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
FR2630440B1 (fr) * 1988-04-25 1991-09-20 Jouveinal Sa Benzodiazepines, leur procede et intermediaires de preparation et leurs applications en therapeutique
EP0411668B2 (en) * 1989-08-04 1998-11-11 MERCK SHARP & DOHME LTD. Central cholecystokinin antagonists for treatment of psychiatric disorders
US5175159A (en) * 1989-10-05 1992-12-29 Merck & Co., Inc. 3-substituted-1,4-benzodiazepines as oxytocin antagonists
CA2026856A1 (en) 1989-10-05 1991-04-06 Mark G. Bock 3-substituted-1,4-benzodiazepines useful as oxytocin
IE904560A1 (en) 1989-12-18 1991-06-19 Merck & Co Inc New benzodiazepine analogs
US5019724A (en) 1989-12-20 1991-05-28 Sgs-Thomson Microelectronics, Inc. Noise tolerant input buffer
US5252463A (en) 1990-06-22 1993-10-12 The Du Pont Merck Pharmaceutical Company Clipsin, a chymotrypsin-like protease and method of using same
GB9022117D0 (en) 1990-10-11 1990-11-21 Beecham Group Plc Novel compounds
GB9107368D0 (en) 1991-04-08 1991-05-22 Smithkline Beecham Plc Novel compounds
US5538845A (en) * 1992-02-05 1996-07-23 Athena Neurosciences, Inc. Beta-amyloid peptide production inhibitors and methods for their identification
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5618812A (en) 1992-07-29 1997-04-08 Merck Sharp & Dohme, Ltd. Benzodiazepine derivatives
US5283241A (en) * 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
EP0674623B1 (en) 1992-12-21 2003-04-09 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
MX9308016A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
JPH07157470A (ja) * 1993-03-18 1995-06-20 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
US5594006A (en) * 1993-03-18 1997-01-14 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives as matrix metalloproteinases inhibitors
EP0763537A3 (en) * 1993-05-14 1997-10-22 Genentech Inc Non-peptides farnesyl transfer inhibitors
EP0702671A4 (en) * 1993-06-09 1996-06-19 Smithkline Beecham Corp BICYCLIC FIBRINOGEN ANTAGONISTS
CZ184194A3 (en) * 1993-08-09 1995-03-15 Lilly Co Eli Aspartylprotease inhibitor and method of identifying thereof
US5602156A (en) * 1993-09-17 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Method for inhibiting metalloproteinase expression
US5545735A (en) 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone
US5426185A (en) * 1993-11-22 1995-06-20 Merck & Co., Inc. Antiarrhythmic benzodiazepines
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
GB9401919D0 (en) * 1994-02-01 1994-03-30 Bridport Aviat Prod Luggage bins for the cabins of passenger aircraft
US5514716A (en) 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
WO1996004254A2 (en) * 1994-07-29 1996-02-15 Fujisawa Pharmaceutical Co., Ltd. Benzodiazepine derivatives
US5661161A (en) * 1994-09-29 1997-08-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1996017833A1 (en) 1994-12-09 1996-06-13 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
JPH10510537A (ja) 1994-12-13 1998-10-13 スミスクライン・ビーチャム・コーポレイション 二環式フィブリノーゲン拮抗薬
US5639746A (en) * 1994-12-29 1997-06-17 The Procter & Gamble Company Hydroxamic acid-containing inhibitors of matrix metalloproteases
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
US5856326A (en) * 1995-03-29 1999-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5578629A (en) * 1995-03-29 1996-11-26 Merck & Co., Inc. Benzamide-containing inhibitors of farnesyl-protein transferase
GB9507799D0 (en) 1995-04-18 1995-05-31 British Biotech Pharm Metalloproteinase inhibitors
US5710171A (en) * 1995-05-24 1998-01-20 Merck & Co., Inc. Bisphenyl inhibitors of farnesyl-protein transferase
DE69533991T2 (de) * 1995-05-29 2006-04-13 Pfizer Inc. Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
US5756528A (en) * 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE19522899C1 (de) * 1995-06-23 1996-12-19 Hexal Pharmaforschung Gmbh Verfahren zum kontinuierlichen Ersintern eines Granulats
JPH09188631A (ja) * 1995-09-08 1997-07-22 Kanebo Ltd Ｆａｓリガンド可溶化抑制薬
EP0761680A3 (en) * 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
WO1997012861A1 (en) 1995-10-05 1997-04-10 Chiroscience Limited Mercaptoamide derivatives and their therapeutic use
IL124366A0 (en) 1995-11-14 1998-12-06 Du Pont Merck Pharma Novel macrocyclic compounds as metalloprotease inhibitors
US6127427A (en) * 1995-11-23 2000-10-03 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
WO1997027852A1 (en) 1996-01-30 1997-08-07 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5968965A (en) * 1996-01-30 1999-10-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000507589A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
US6001835A (en) * 1996-04-03 1999-12-14 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5869682A (en) * 1996-04-03 1999-02-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5965578A (en) * 1996-04-03 1999-10-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5891889A (en) * 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5919785A (en) * 1996-04-03 1999-07-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5859012A (en) * 1996-04-03 1999-01-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5885995A (en) * 1996-04-03 1999-03-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5852010A (en) * 1996-04-03 1998-12-22 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036900A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000507587A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシルタンパク質トランスフェラーゼ阻害剤
DE19614100C2 (de) * 1996-04-10 2000-12-07 Bosch Gmbh Robert Vorrichtung zur Ermittlung des Zustandes eines Wischerblattes
WO1997038664A2 (en) 1996-04-18 1997-10-23 Merck & Co., Inc. A method of treating cancer
EP0934270A1 (en) 1996-05-30 1999-08-11 Merck & Co., Inc. A method of treating cancer
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
WO1998015828A1 (en) 1996-10-07 1998-04-16 Scios Inc. Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase
US6262047B1 (en) * 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
JP2001504810A (ja) 1996-10-11 2001-04-10 シーオーアール・セラピューティックス・インコーポレーテッド 選択的第Ｘａ因子阻害剤
US5734054A (en) * 1996-11-05 1998-03-31 Pharmacopeia, Inc. Hydroxy-amino acid amides
DE19647382A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
KR20000069075A (ko) 1996-11-22 2000-11-25 진 엠. 듀발 Ｎ-(아릴/헤테로아릴/알킬아세틸)아미노산 아미드, 이들을 함유하는 제약 조성물, 및 이들 화합물을 사용하여 베타-아밀로이드 펩티드의 방출 및(또는) 합성의 억제 방법
AU739035B2 (en) 1996-11-22 2001-10-04 Elan Pharmaceuticals, Inc. N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
WO1998022441A2 (en) 1996-11-22 1998-05-28 Elan Pharmaceuticals, Inc. N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions, and methods for inhibiting beta-amyloid peptide and/or its synthesis
WO1998022493A2 (en) 1996-11-22 1998-05-28 Elan Pharmaceuticals, Inc. N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
KR20000069654A (ko) 1996-12-23 2000-11-25 엘란 파마슈티칼스, 인크. 시클로알킬, 락탐, 락톤 및 관련 화합물, 그의 약제학적 조성물및 그를 사용한 β-아밀로이드 펩티드의 방출 및(또는) 합성억제 방법
US6093737A (en) * 1996-12-30 2000-07-25 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU6013998A (en) 1996-12-30 1998-07-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2002241368A (ja) * 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6060038A (en) * 1997-05-15 2000-05-09 Merck & Co., Inc. Radiolabeled farnesyl-protein transferase inhibitors
DE19726427A1 (de) * 1997-06-23 1998-12-24 Boehringer Mannheim Gmbh Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
GB9715030D0 (en) * 1997-07-18 1997-09-24 British Biotech Pharm Metalloproteinase inhibitors
US6333321B1 (en) * 1997-08-11 2001-12-25 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6228854B1 (en) * 1997-08-11 2001-05-08 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6297239B1 (en) * 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6440965B1 (en) * 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system

Also Published As

Publication number Publication date
AU5337899A (en) 2000-02-28
ES2251838T3 (es) 2006-05-01
US20060258638A1 (en) 2006-11-16
US20060264417A1 (en) 2006-11-23
DE69927827D1 (de) 2006-03-02
US7304056B2 (en) 2007-12-04
EP1102752A1 (en) 2001-05-30
AU756830B2 (en) 2003-01-23
JP2003526603A (ja) 2003-09-09
CN1311779A (zh) 2001-09-05
US7304055B2 (en) 2007-12-04
AR024197A1 (es) 2002-09-25
DE69927827T2 (de) 2006-07-06
HRP990246A2 (en) 2000-06-30
EP1102752B1 (en) 2005-10-19
CA2338944A1 (en) 2000-02-17
ATE307117T1 (de) 2005-11-15
BR9912969A (pt) 2001-09-25
WO2000007995A1 (en) 2000-02-17

Similar Documents

Publication Publication Date Title
TR200100377T2 (tr) Aß Protein üretimi inhibitörleri olarak sukinoilamino laktamlar.
WO2000038618A3 (en) SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
WO2001060826A3 (en) SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
PT721449E (pt) Inibidores da producao da proteina beta-amiloide
CA2379445A1 (en) Lactams substituted by cyclic succinates as inhibitors of a.beta. protein production
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
WO2000047568A3 (en) 1,2-benzothiazepines for the treatment of hyperlipidemic diseases
EA200300788A1 (ru) Производные замещенных алкиламинов и их применение
EA200200111A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
DE60219954D1 (de) Neue Indol-2-on Derivate
EA200400162A1 (ru) N-(3-амино-2-гидроксипропил)замещенные алкиламидные соединения
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
ATE253918T1 (de) Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel
TW200502221A (en) Novel lactams and uses thereof
MXPA02001813A (es) Hidroxialcanoilaminolactamas y estructuras relacionas como inhibidores de la produccion de la proteina abeta.
BG104983A (en) Aryl fused azapolycyclic compounds
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
TW200504036A (en) Novel lactams and uses thereof
ZA200209714B (en) Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV.
AR022292A1 (es) Succinoilamino benzodiazepinas como inhibidoras de la produccion de proteinas a beta
CA2270026A1 (en) Substituted bicyclic derivatives for treating central nervous system disorders
UA40655C2 (uk) Засіб для лікування гнійно-некротичних процесів